Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AeriSeal is a bronchoscopically delivered foam lung sealant system designed to achieve lung volume reduction or closure of collateral ventilation in patients with advanced chronic obstructive pulmonary disease (COPD) and emphysema. The system instills a polymerizing foam into peripheral airways and alveoli, where it acts as a tissue glue to occlude target regions or fissure gaps, collapse diseased lung segments, and reduce hyperinflation, thereby improving respiratory mechanics, lung function, and symptoms in patients who are poor candidates for surgical lung volume reduction or who have collateral ventilation that precludes valve-only therapy.[1][2][4][5][8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AeriSeal.